Nevro said it has received approval from the U.S. Food and Drug Administration for a randomized, controlled pivotal clinical trial in the United States.
The Menlo Park-based private medical device company is focused on improving pain relief for patients suffering from debilitating chronic pain. The trial will be to evaluate its spinal cord stimulation system for treating chronic pain.
The trial is expected to include about 300 patients.